Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SkyePharma and Sciele Pharma have reported that the FDA has approved all four dosage strengths of the new Sular formulation.
Subscribe to our email newsletter
Sular is a calcium channel blocking agent for the treatment of high blood pressure. The new Sular formulation utilizes SkyePharma’s patented Geomatrix technology, which provides a lower dose of Sular for each of its current doses. The new Sular formulation is expected to be launched during the first quarter of 2008.
SkyePharma will manufacture the new Sular formulation at Lyon manufacturing facility and will receive $2 million upon the approval and also low mid single digit royalties on net sales of new Sular.
Ken Cunningham, chief operating officer of SkyePharma, said: “This new Sular formulation is a further example of the versatility of the Geomatrix technology and will provide an additional revenue stream for SkyePharma.”